Galapagos NV (AMS:GLPG)
Netherlands
· Delayed Price · Currency is EUR | Market Cap | 1.65B |
| Revenue (ttm) | 275.65M |
| Net Income (ttm) | 74.08M |
| Shares Out | 65.90M |
| EPS (ttm) | 1.12 |
| PE Ratio | 22.22 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,296 |
| Average Volume | 122,977 |
| Open | 25.08 |
| Previous Close | 24.98 |
| Day's Range | 25.00 - 25.76 |
| 52-Week Range | 21.70 - 32.34 |
| Beta | 0.00 |
| RSI | 57.50 |
| Earnings Date | Feb 12, 2025 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.
Financial StatementsNews
Galapagos to Present at Upcoming Investor Conferences
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and in...
Galapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)
Disount To Net Cash For A Promising CAR-T Company
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell ...
Galapagos receives transparency notification and 13D filing from Tang Capital
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of Galapagos NV Shares
TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of Galapagos NV Shares
Galapagos downgraded at Morgan Stanley on new pipeline focus
Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript
Galapagos NV 2024 Q4 - Results - Earnings Call Presentation
Galapagos GAAP EPS of €1.12, revenue of €275.6M
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein
Galapagos FY 2024 Earnings Preview
Galapagos inks agreement with Catalent for experimental CAR-T therapy
Catalent will manufacture an experimental CAR-T therapy for non-Hodgkin lymphoma from Galapagos for use in trials. Read more here.
Galapagos To Spin Off Innovative Medicines Business
On January 8, 2025, Galapagos NV. (US Nasdaq ADR: GLPG; $23.76, Market Capitalization: $1.56 billion), announced its plans to split into two listed entities by mid-2025 by spinning off its activities ...
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Galapagos NV (NASDAQ: GLPG) has unveiled plans to divide its operations into two entities, aiming to enhance shareholder value and sharpen strategic focus . One entity, referred to as SpinCo, will pr...
Biotech Firm Galapagos to Split Into Two Entities, Cut Jobs
Belgian biotech company Galapagos NV plans to spin off part of its operations, creating a new listed firm with approximately €2.45 billion ($2.5 billion) in cash.
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, ...
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5...
Galapagos NV (GLPG) Stock Surges Amid Strong Industry Performance
Galapagos NV (GLPG) Stock Surges Amid Strong Industry Performance
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th Americ...
Galapagos NV 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Galapagos NV in conjunction with their 2024 Q3 earnings call.
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ETCompany ParticipantsSofie Van Gijsel - Head of IRPaul Stoffels -...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
Webcast presentation on October 31, 2024, at 1 3 :00 CET / 8:00 am ET, www.glpg.com
EcoR1 Capital, LLC Increases Stake in Galapagos NV
EcoR1 Capital, LLC Increases Stake in Galapagos NV
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director...